STATUTORY RULES OF NORTHERN IRELAND

2014 No. 20

DANGEROUS DRUGS

The Misuse of Drugs (Designation) (Amendment) Order (Northern Ireland) 2014

Made - - - -	*3rd February 2014*
Coming into force - -	*24th February 2014*

The Department of Health, Social Services and Public Safety makes the following Order in exercise of the powers conferred by section 7(4) of the Misuse of Drugs Act 1971(**1**) as adapted by section 38 of that Act and now vested in it (**2**) and after consultation with the Advisory Council on the Misuse of Drugs in accordance with section 7(7) of that Act.

Citation, commencement and interpretation

1.—(1) This Order may be cited as the Misuse of Drugs (Designation) (Amendment) Order (Northern Ireland) 2014 and shall come into operation on 24th February 2014.

(2) The Interpretation Act (Northern Ireland) 1954(**3**) shall apply to these Regulations as it applies to an Act of the Assembly.

Amendments to the Misuse of Drugs (Designation) Order 2001

2. Part 1 of the Schedule to the Misuse of Drugs (Designation) Order (Northern Ireland) 2001 (which specifies controlled drugs to which section 7(4) of the Misuse of Drugs Act 1971 applies) shall be amended as provided by Articles 3 to 7.

3. In paragraph 1(a) after "*N, N*-Diethyltryptamine", insert—

"2-((Dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol".

4. For paragraph 1(1), (m), (n) and (o)(**4**), substitute—

"(1) Any compound structurally derived from 3-(1-naphthoyl)indole,3-(2-naphthoyl)indole, 1*H*-indol-3-yl-(1-naphthyl)methane or 1*H*-indol-3-yl-(2-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkeny1, cyanoalky1, hydroxyalky1, cycloalkylmethyl, cycloalkylethyl, (*N*-

(**1**) 1971 c.38
(**2**) SR & O (NI) 1973 No.504, Article 5 (a) and S.I. 1999 No.283 (NI.1) Article 3(6)
(**3**) 1954 c.33 (N.I.)
(**4**) Paragraph 1(1), (m), (n) and (o) was inserted by article 3(c) of S.R. 2009 No.389

methylpiperidin-2-yl)methyl or 2-(4-morpholiny)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.

(m) Any compound structurally derived from 3–(1–naphthoyl)pyrrole or 3-(2-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent.

(n) Any compound structurally derived from 1–(1–naphthylmethylene)indene or 1-(2-naphthylmethylene)indene by substitution at the 3–position of the indene ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent.

(o) Any compound structurally derived from 3–phenylacetylindole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.".

5. After paragraph 1(p)(**5**) insert—

"(pa) Any compound structurally derived from 3-benzoylindole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.

(pb) Any compound structurally derived from 3-(1-adamantoyl)indole or 3-(2-adamantoyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent.

(pc) Any compound structurally derived from 3-(2,2,3,3-tetramethylcyclopropylcarbonyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholiny)ethyl, whether or not further substituted in the indole ring to any extent.".

6. After paragraph 1(s)(**6**), insert—

"(t) 1-Phenylcyclohexylamine or any compound (not being eticyclidine, ketamine, phencyclidine, rolicyclidine, tenocyclidine or tiletamine) structurally derived from 1-phenylcyclohexylamine or 2-amino-2-phenylcyclohexanone by modification in any of the following ways, that is to say,

(i) by substitution at the nitrogen atom to any extent by alkyl, alkenyl or hydroxyalkyl groups, or replacement of the amino group with a 1-piperidyl,

(**5**) Paragraph 1(p) was inserted by article 3(c) of S.R. 2009 No.389
(**6**) Paragraph 1(s) was inserted by article 3(c) of S.R. 2012 No.212